U25. NMR: Biomedical Applications I
- Scientific Director: Prof. Carles Arús Carles.Arus@uab.es
- Scientific Coordinator: Ana Paula Candiota AnaPaula.Candiota@uab.cat
- Entities: Servicio de Resonancia Magnética Nuclear (SeRMN) & Institut de Biotecnología i Biomedicina (IBB) & Universidad Autónoma de Barcelona (UAB)
- Address: Facultad de Ciencias, Edificio C, 08193, Cerdanyola del Vallés, Barcelona, Spain
- Phone: +34 935 814 126
- Web: GABRMN-UAB seRMN-UAB
The platform is divided between the Servei de Ressonància Magnètica Nuclear (Nuclear Magnetic Resonance Facility) (SeRMN) (http://sermn.uab.cat/) and the Institut de Biotecnologia i Biomedicina (IBB) for bioinformatics applications of the UAB . This platform is coordinated by Prof. Carles Arús, PI of the Nuclear Magnetic Resonance Biomedical Applications Group (GABRMN) (http://gabrmn.uab.es/), with a recognized research track record in the use of NMR as a tool for biomedical applications, and more especifically to identify biomarkers of different pathologies. The main objective of the Platform of Biomedical Applications of Nuclear Magnetic Resonance at the Universitat Autònoma de Barcelona (UAB) is the acquisition, processing and/or interpretation of Nuclear Magnetic Resonance data.
The platform is equipped with 10 spectrometers operating at magnetic fields between 5.8 and 14.1 Teslas (T), including a MRI scanner, Bruker BioSpec, equipped with a 7T horizontal magnet for preclinical trials.
The unit also hosts a computational platform at the IBB, with a total storage capacity of 12TB, which is accessible through the UAB network. The computational platform also hosts two multicentre databases (INTERPRET and eTUMOUR), with NMR and clinical data for more than 1000 human brain tumour patients.
The uniqueness in this case lies in access, in the same location, equipment for NMR studies in vivo, ex vivo and in vitro, molecular imaging accessories by using polarization as well as fixed metabolomic patterns. This configuration allows to validate results of molecular imaging in vivo with other in vitro facilities.
- U25-S01. NMR spectrometer 250MHz robot/250MHz auto/360MHz/400MHZ (Onsite&Remote) OUTSTANDING
- U25-S02. NMR spectrometer 500MHz/600MHz (Onsite&Remote) OUTSTANDING
- U25-S03. NMR spectrometer 400 MHz with HRMAS/CPMAS probes (Onsite&Remote) OUTSTANDING
- U25-S04. 500 MHz spectrometer HPLC-NMR(Onsite&Remote) OUTSTANDING
- U25-S05. Preclinical horizontal spectrometer Biospec 7T (Onsite&Remote) OUTSTANDING
- U25-S06. Dynamic nuclear polarizer HyperSense® (Onsite&Remote) OUTSTANDING
- U25-S07. Focused Microwave Fixation system (Onsite&Remote) OUTSTANDING
- U25-S09. Access to specific software and database (Remote) OUTSTANDING
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
- U25-E01. Two AVANCE 250 MH z
- U25-E02. An AVANCE 360 MH z
- U25-E03. AVII 400 MH z
- U25-E04. AVIII 400 MH z
- U25-E05. AVANCE 500 MH z
- U25-E06. AVIII 600 MH z
- U25-E07. BioSpec 70/30 300 MH z
- U25-E08. Focused Microwave Fixation System
- U25-E09. Hypersense sample polarizer
In addition to the indicated equipment, it has:
- U25-E10. Animal housing
- U25-E11. Software packages
- AMIX software page (http://www.bruker-biospin.com/amix.html): analysis of mixtures, metabolomic studies, etc.
- INTERPRET decision-support system for human brain tumour diagnosis (based on MRS and SpectraClassifier)
- Databases of human brain tumour data.
|Title||Fundin: Organism||Call: Funding source||Role|
|SAF2017-90810-REDI||Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II||Agencia Estatal de Investigación (AEI)||Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017||Coordinator|
- Delgado-Goni T., Ortega-Martorell S., Ciezka M., Olier I., Candiota A.P., Julia-Sape M. et al. MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine. 2016;:-.
- Cordon-Barris L., Pascual-Guiral S., Yang S., Gimenez-Llort L., Lope-Piedrafita S., Niemeyer C. et al. Mutation of the 3-phosphoinositide-dependent protein kinase 1 (PDK1) substrate-docking site in the developing brain causes microcephaly with abnormal brain morphogenesis independently of akt, leading to impaired cognition and disruptive behaviors. Molecular and Cellular Biology. 2016;36(23):2967-2982.
- Ferrer-Font L., Alcaraz E., Plana M., Candiota A.P., Itarte E., Arus C.. Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathology and Oncology Research. 2016;:-.
- Ciezka M., Acosta M., Herranz C., Canals J.M., Pumarola M., Candiota A.P. et al. Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation. Journal of Neuro-Oncology. 2016;:1-10.
Preclinical brain tumour therapy response assessment with MRSI approaches: Oral presentation awarded to Ana Paula Candiota
NANBIOSIS U25 scientific coordinator, Ana Paula Candiota, has recently presented a scientific work about preclinical brain tumour therapy response assessment with MRSI approaches in the 36th annual meeting of ESMRMB held in Rotterdam, Netherlands, October 3-5. Work was entitled “Oscillatory pattern of response in MRSI-based Glioblastoma therapy follow-up: an immune system biomarker?” and was awarded an oral presentation in the scientific session of Animal Models: Brain & others Article of refrence: L. Villamañan, P. Calero, S. Wu, N. Arias-Ramos, M. Pumarola, S. Ortega-Martorell, M. Julià-Sapé, C. Arús, A.P. Candiota. Oscillatory pattern of response in MRSI-based Glioblastoma therapy follow-up: an immune system[...]
The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, places the Autonomous University of Barcelona among the elite of the 300 best universities in the world. This indicator organizes up to 20,000 university centers worldwide, based on transparent methodology and objective third-party data. ARWU is regarded as one of the three most influential and widely observed university rankings The Autonomous University of Barcelona houses two of NANBIOSIS Units: U1 Protein Production Platform (PPP), led by Toni Villaverde, Neus Ferrer and Paolo Saccardo, offer an “tailored” service for the design, production and purification[...]
Ana Paula Candiota, Scientific coordinator of U25 of NANBIOSIS, is the IP of the granted project Multiparametric MR approaches for non-invasive Glioblastoma therapy response follow-up (MAGRes), selected for funding in the ATTRACT call https://attract-eu.com/the-project/ The kick-off meeting for is taking place at CERN, Switzerland, days 20-21th May with talks of all selected projects. Unit 25 will have a relevant role in the development of MAGRes. MRI/MRSI from preclinical brain tumors will be acquired at NANBIOSIS U25, NMR: Biomedical Applications I[...]
Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge the efforts made by scientific women who struggle every day to contribut[...]
The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]
Margarida Julià‐Sapé, Ana Paula Candiota and Carles Arús, Scientific Director and Scientific Coordinators of Nanbiosis U25 NMR: Biomedical Applications I, are the authors of a new article in the journal NMR in Biomedicine: “Cancer metabolism in a snapshot: MRS(I)” The article contains a revision of the contribution of MRS(I) to the in vivo evaluation of cancer‐metabolism‐derived metrics, mostly since 2016. Strategies include the following: (1) quantification of single oncometabolite content such as 2HG; (2) selected metabolite ratios such as total Cho to NAA in gliomas, ratios related to Cho, Cr, citrate and polyamines in prostate cancer or Lac/Pyr in hyperpolarized[...]
Ana Paula Candiota and Carles Arús, Scientific Cordinator and Scientific Director of U25 of NANBIOSIS, NMR: Biomedical Applications I have participated in the research published by ACS Applied Materials & Interfaces Journal that include a preclinical study carried for brain Tumor. Extensive attention has been paid on designing and developing functional imaging contrast agents for providing accurate noninvasive evaluation of pathology in vivo. However, alse-positives or ambiguous imaging and the lack of a robust strategy for simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for improving it is to design magnetic resonance imaging (MRI) contrast agents (CAs) wit[...]
Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I. is givin a talk about “Nosological images of response to therapy based on metabolomic information by magnetic resonance: a step beyond the standard image” next June 6, on Barcelona. According to Dr. Candiota, “The reliable characterization of the treatment response in glioblastoma (GB) is a key factor in improving the survival and prognosis of patients. Image (MRI) and spectroscopic image (MRSI) by magnetic resonance respectively provide morphological and metabolotic profiles of GB, but in general they are not as robust to produce surrogate biomarkers in response to short-term[...]